Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of Saturday, August 1, 2026.
Forward PE Ratio (N/A) = Close Price ($47.08) / Consensus Forward EPS ($21.42)
FORWARD PE RATIO
N/A
Novo Nordisk A/S
Market Cap
$209.19B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Novo Nordisk A/S (NVO) | $209.19B | N/A |
| Amgen Inc. (AMGN)vs › | $207.87B | 17.23 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $213.42B | 22.89 |
| Abbott Laboratories (ABT)vs › | $184.11B | 19.17 |
| Gilead Sciences, Inc. (GILD)vs › | $161.66B | N/A |
| Pfizer Inc. (PFE)vs › | $142.54B | 8.50 |
| Danaher Corporation (DHR)vs › | $137.13B | 22.96 |
| Bristol-Myers Squibb Company (BMY)vs › | $133.37B | 9.88 |
| CVS Health Corp. (CVS)vs › | $133.25B | 14.02 |
| AstraZeneca PLC (AZN)vs › | $131.47B | 16.55 |
Trailing P/E
11.0
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $21.42 implies +401.6% EPS growth vs the reported trailing $4.27.
At today's $47.08 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $21.42 | $19.40 – $23.63 | 7 | 2.2x |
| 2027-12-31 | $21.44 | $20.20 – $24.26 | 7 | 2.2x |
| 2028-12-31 | $23.18 | $20.96 – $26.29 | 5 | 2.0x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
